Takeda and Samyang form research collaboration

Published: 13-Apr-2011

On the discovery of novel DDS Platform technology for RNAi therapeutics


Takeda Pharmaceutical Company of Japan and Samyang Corporation of Korea are to collaborate on the discovery of a novel DDS platform technology for RNA interference (RNAi) therapeutics.

Under the terms of the agreement, Takeda and Samyang, a Seoul-based developer of drug delivery technologies, will conduct research to develop the DDS technology based on Samyang’s technology in three years, or longer if necessary.

Takeda will make an upfront payment to Samyang and also bear research costs during the collaboration period.

Samyang is eligible to receive milestone payments and sales-based royalties from Takeda.

‘We expect that the great synergy between our high-level DDS expertise and Takeda’s proven strength in pharmaceutical research and development will lead to RNAi therapeutics of high added-value,’ said Cheolho Kwak, coo of Samyang’s Bio & Pharmaceuticals Group.

You may also like